Dyspepsia Market Research Report – Forecast to 2027

Dyspepsia Market Research Report, by Diagnosis ( Blood Tests, Breath Tests, Stool Tests ), Treatment  (Antacids, Antibiotics, H2 Blockers, Proton Pump Inhibitors), End-User  (Hospital, Clinic, Ambulatory Surgical Centre) - Forecast Till 2027

ID: MRFR/Pharma/4890-HCR | | Region: Global | 100 Pages         

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Dyspepsia Market, by Diagnosis

6.1 Introduction

6.2 Blood Tests

6.3 Breath Tests

6.4 Stool Tests

6.5 Endoscopy

6.6 X-ray

6.7 CT scan

6.8 Others

Chapter 7. Global Dyspepsia Market, by Treatment

7.1 Introduction

7.2 Antacids

7.2.1 Calcium Carbonate

7.2.2 Loperamide

7.2.3 Simethicone

7.2.4 Sodium Bicarbonate

7.2.5 Others

7.3 Antibiotics

7.3.1 Amoxicillin

7.3.2 Clarithromycin

7.3.3 Metronidazole

7.3.4 Others

7.4 H2 Blockers

7.4.1 Cimetidine

7.4.2 Famotidine

7.4.3 Nizatidine

7.4.4 Ranitidine

7.4.5 Others

7.5 Proton Pump Inhibitors (PPIs)

7.5.1 Esomeprazole

7.5.2 Lansoprazole

7.5.3 Omeprazole

7.6 Prokinetics

7.6.1 Bethanechol

7.6.2 Metoclopramide

7.7 Psychological Therapies

7.8 Others

Chapter 8. Global Dyspepsia Market, by End-User

8.1 Introduction

8.2 Hospitals and Clinics

8.3 Ambulatory Surgical Centers

8.4 Pharmacies

8.5 Diagnostic Centers

8.6 Others

Chapter 9. Global Dyspepsia Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 AstraZeneca

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 GlaxoSmithKline

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Takeda Pharmaceutical Company

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Johnson & Johnson

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Eisai Co., Ltd

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Abbott Laboratories

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 SALIX PHARMACEUTICALS

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Bayer AG

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Boehringer Ingelheim GmbH

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Sanofi

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Allergan Plc

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

Chapter 12 Appendix

LIST OF TABLES

Table 1 Dyspepsia Market Industry Synopsis, 2020–2027

Table 2 Global Dyspepsia Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Dyspepsia Market, by Region, 2020–2027, (USD Million)

Table 4 Global Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 5 Global Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table6 Global Dyspepsia Market, by End-User, 2020–2027, (USD Million

Table7 North America: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 8 North America: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 10 US: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 11 US: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 12 US: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 Canada: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 16 South America: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 17 South America: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe: Dyspepsia Market, Diagnosis, 2020–2027, (USD Million)

Table 20 Europe: Dyspepsia Market, Type, 2020–2027, (USD Million)

Table 21 Europe: Dyspepsia Market, Technology, 2020–2027, (USD Million)

Table 32 Europe: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 23 Europe: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 24 Western Europe: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 25 Western Europe: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 26 Western Europe: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 27 Eastern Europe: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 28 Eastern Europe: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 29 Eastern Europe: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 30 Asia-Pacific: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 31 Asia-Pacific: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 32 Asia-Pacific: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

Table 33 Middle East & Africa: Dyspepsia Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Middle East & Africa: Dyspepsia Market, by Treatment, 2020–2027, (USD Million)

Table 35 Middle East & Africa: Dyspepsia Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Dyspepsia Market

Figure 3 Market Dynamics for Global Dyspepsia Market

Figure 4 Global Dyspepsia Market Share, by Diagnosis 2020

Figure 5 Global Dyspepsia Market Share, by Treatment 2020

Figure 6 Global Dyspepsia Market Share, by End-User, 2020

Figure 7 Global Dyspepsia Market Share, by Region, 2020

Figure 8 North America Dyspepsia Market Share, by Country, 2020

Figure 9 Europe Dyspepsia Market Share, by Country, 2020

Figure 10 Asia-Pacific Dyspepsia Market Share, by Country, 2020

Figure 11 Middle East & Africa Dyspepsia Market Share, by Country, 2020

Figure 12 Global Dyspepsia Market: Company Share Analysis, 2020 (%)

Figure 13 AstraZeneca: Key Financials

Figure 14 AstraZeneca: Segmental Revenue

Figure 15 AstraZeneca: Geographical Revenue

Figure 16 GlaxoSmithKline: Key Financials

Figure 17 GlaxoSmithKline: Segmental Revenue

Figure 18 GlaxoSmithKline: Geographical Revenue

Figure 19 Takeda Pharmaceutical Company : Key Financials

Figure 20 Takeda Pharmaceutical Company : Segmental Revenue

Figure 21 Takeda Pharmaceutical Company : Geographical Revenue

Figure 22 Johnson & Johnson : Key Financials

Figure 23 Johnson & Johnson : Segmental Revenue

Figure 24 Johnson & Johnson : Geographical Revenue

Figure 25 Abbott Laboratories : Key Financials

Figure 26 Abbott Laboratories : Segmental Revenue

Figure 27 Abbott Laboratories : Geographical Revenue

Figure 28 Eisai Co., Ltd : Key Financials

Figure 29 Eisai Co., Ltd : Segmental Revenue

Figure 30 Eisai Co., Ltd : Geographical Revenue

Figure 31 SALIX PHARMACEUTICALS : Key Financials

Figure 32 SALIX PHARMACEUTICALS : Segmental Revenue

Figure 33 SALIX PHARMACEUTICALS : Geographical Revenue

Figure 34 Bayer AG: Key Financials

Figure 35 Bayer AG: Segmental Revenue

Figure 36 Bayer AG: Geographical Revenue

Figure 37 Boehringer Ingelheim GmbH : Key Financials

Figure 38 Boehringer Ingelheim GmbH : Segmental Revenue

Figure 39 Boehringer Ingelheim GmbH : Geographical Revenue

Figure 40 Sanofi: Key Financials

Figure 41 Sanofi: Segmental Revenue

Figure 42 Sanofi: Geographical Revenue

Figure 43 Allergan Plc: Key Financials

Figure 44 Allergan Plc: Segmental Revenue

Figure 45 Allergan Plc: Geographical Revenue

Dyspepsia Market Scenario:


The dyspepsia market is expected to witness a positive growth during the forecast period. Dyspepsia is a chronic medical condition, that causes discomfort in the upper abdomen of the patient due to indigestion. The gastrointestinal organs, the stomach and the small intestine (sometimes the esophagus), do not function normally. Gastrointestinal causes of dyspepsia are gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced blood flow in the intestine (intestinal ischemia). Nongastrointestinal causes are diabetes, thyroid disease, kidney disease and consumption of drugs like nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), antibiotics and others. Dyspepsia is also caused due to overeating, smoking and extreme consumption of alcohol. The increasing prevalence of digestive diseases is the key factor for the market to grow. According to the Centers for Disease Control and Prevention in 2016, 14.7 million people in the US suffered from digestive ulcers. Such a high prevalence of digestive diseases enhances the market growth during the forecast period. Other factors like growing caffeine intake, increasing alcohol consumption, rising prevalence of diabetes, increasing incidences of thyroid diseases and stomach cancer, robust R&D activities to develop new drugs and advancement in diagnosis and treatment technologies is driving the growth of the market.


However, factors such as expensive diagnosis test and intense competition among the major market players to gain maximum market share are expected to restrict the market growth during the forecast period.


Segmentation


The global dyspepsia market is segmented on the basis of diagnosis, treatment, and end-user. The dyspepsia market, by diagnosis, is sub-segmented into blood tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others. On the basis of treatment, the market is categorized into antacids, antibiotics, h2 blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies and others. Antacids are further sub-segmented into calcium carbonate, loperamide, simethicone, sodium bicarbonate and others. Antibiotics further sub-segmented into amoxicillin, clarithromycin,  metronidazole, and others. H2 blockers are further categorized into cimetidine, famotidine, nizatidine, ranitidine, and others.  Proton pump inhibitors (PPIs) is further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics are categorized into bethanechol and metoclopramide. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, pharmacies, diagnostic centers and others.


On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key Players



  • AstraZeneca

  • GlaxoSmithKline

  • Takeda Pharmaceutical Company

  • Johnson & Johnson

  • Eisai Co., Ltd

  • Abbott Laboratories

  • Salix Pharmaceuticals

  • Bayer AG

  • Boehringer Ingelheim GmbH

  • Sanofi, Allergan Plc


Regional Market Summary

Global Dyspepsia Market Share (%), by Region, 2017


Dyspepsia Market Share


Sources: United European Gastroenterology, Cancer Research, the Centers for Disease Control and Prevention


The dyspepsia market is dominated by North America owing to rising prevalence of ulcerative colitis.


Ulcerative Colitis causes inflammation of the digestive tract which may lead to dyspepsia. According to the Centers for Disease Control and Prevention in 2015, 3 million people suffered from ulcerative colitis. Also, the increased adoption of technologically advanced devices and the high amount of healthcare expenditure drives the market growth in this region.


It is estimated that Europe stood second in the global dyspepsia market. Thus, increasing prevalence of chronic digestive disease in Europe contributes to market growth. According to the United European Gastroenterology report published in 2018, 365,000 deaths in Europe were due to digestive cancers. Also, rising healthcare expenditure and R&D activities are driving the growth of this market in Europe.


Asia-Pacific was projected to be the fastest growing region for the global dyspepsia market. Key factors such as rising number of patient population, increase in the adoption of minimally invasive surgeries, and rapid rise in endoscopy for the diagnosis and treatment of digestive diseases, influences the market in this region. Also, the rising medical tourism in countries like Malaysia, India, and Thailand drives market growth in this region.


The Middle East and Africa holds the least share of the global dyspepsia market due to the presence of stringent government policies and poor economies. However, increasing investment by private market players and growing government initiatives in this region can boost the market growth. 


Market Segmentation and Key Market Players


Global Dyspepsia Market, by Diagnosis



  • Blood Tests

  • Breath Tests

  • Stool Tests

  • Endoscopy

  • X-ray

  • CT scan

  • Others


Global Dyspepsia Market, by Treatment



  • Antacids

    • Calcium Carbonate

    • Loperamide

    • Simethicone

    • Sodium Bicarbonate

    • Others



  • Antibiotics

    • Amoxicillin

    • Clarithromycin

    • Metronidazole

    • Others



  • H2 Blockers



  • Cimetidine

  • Famotidine

  • Nizatidine 

  • Ranitidine

  • Others



  • Proton Pump Inhibitors (PPIs)



  • Esomeprazole 

  • Lansoprazole

  • Omeprazole

  • Prokinetics

  • Bethanechol

  • Metoclopramide



  • Psychological Therapies


Global Dyspepsia Market, by End-User



  • Hospitals and clinics

  • Ambulatory surgical centers

  • Pharmacies

  • Diagnostic centers

  • Others


Global Dyspepsia Market, by Region



  • The Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2019-2027:Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Application, And End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca, GlaxoSmithKline, Takeda Pharmaceutical Company, Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Salix Pharmaceuticals, Bayer AG, Boehringer Ingelheim GmbH, Sanofi, Allergan Plc, and others.
  Key Market Opportunities   Research & Development
  Key Market Drivers

  • Rising prevalence of diabetes
  • Increasing incidences of thyroid diseases and stomach cancer
  • Robust R&D activities to develop new drugs
  • Advancement in diagnosis and treatment technologies


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The dyspepsia market would be hindered by costly diagnostic procedures.

    The leading region would be the Americas for the dyspepsia market.

    End users profiled for dyspepsia market are ambulatory surgical centers, hospitals & clinics, diagnostic centers, pharmacies, and others.

    The diagnosis-based treatments are breath tests, blood tests, endoscopy, stool tests, CT scans, X-rays, and others.

    The treatment-based studies for dyspepsia market include antibiotics, antacids, proton pump inhibitors (PPIs), h2 blockers, psychological therapies, prokinetics, and others.